Abstract

Acute diarrhea is a major cause of morbidity and mortality in children under five. Probiotics are beneficial for treating acute diarrhea in children, but unclear which specific probiotic is the most effective. We performed a Bayesian network meta-analysis to examine the comparative effectiveness of probiotics. By searching EMBASE, PubMed, and the Cochrane Library up to 31 March 2021, randomized clinical trials (RCTs) on probiotics for treating acute diarrhea in children were included. Primary outcomes included the duration of diarrhea and diarrhea lasting ≥2 days, and secondary outcomes included the mean stool frequency on day 2 and duration of hospitalization, fever, and vomiting. We assessed the certainty of the evidence of outcomes according to Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guideline. Eighty-four studies with twenty-one different interventions in 13,443 children were included. For the primary outcomes, moderate evidence indicated that, Lactobacillus reuteri [mean difference (MD) = −0.84 day; 95% confidence interval (CI), −1.39, −0.29], Bifidobacterium lactis (MD = −0.98 day; 95%CI, −1.82, −0.14), Saccharomyces boulardii (MD = −1.25 day; 95%CI, −1.59, −0.91), Lactobacillus species (spp.) plus Bifidobacterium spp. plus Saccharomyces spp. (MD = −1.19 day; 95%CI, −1.81, −0.58), and Bacillus spp. plus Enterococcus spp. plus Clostridium spp. (MD = −1.1 day; 95%CI, −1.84, −0.35) significantly reduced the duration of diarrhea when compared with placebo. Saccharomyces boulardii [Odds ratio (OR) = 0.22; 95%CI, 0.11, 0.41] and Lactobacillus reuteri (OR = 0.23; 95%CI, 0.090, 0.60) significantly reduced the risk of diarrhea lasting ≥2 days when compared with placebo or no treatment, with moderate evidence. Among all probiotics, Saccharomyces boulardii may be the most effective in reducing both duration of diarrhea (compared with placebo) and risk of diarrhea lasting ≥2 days (compared with placebo or no treatment), with moderate evidence. To be conclusive, Saccharomyces boulardii may be the most effective probiotic for treating acute diarrhea in children, followed by several other single-strain and multi-strain probiotics.

Highlights

  • Diarrhea is common among infants, usually acute, which is mainly caused by infection [1]

  • A total of 3927 records were retrieved by searching EMBASE, PubMed, and the Cochrane Library

  • In the network meta-analysis (NMA), we included eighty-four randomized controlled trials with a total of 13,443 children involving twenty-one interventions to illustrate the clinical effect of probiotics for treating acute diarrhea

Read more

Summary

Introduction

Diarrhea is common among infants, usually acute, which is mainly caused by infection [1]. In 2017, diarrhea accounted for 533,768 deaths among children under five, mainly in developing countries [2]. World Health Organization defines diarrhea as three or more loose or watery stools within 24 h, and diarrhea is classified as acute if the duration of diarrhea is less than 14 days [3]. Diarrhea could result in dehydration and electrolyte disturbances in children. Significant consequences related to diarrhea in children include growth stunting, malnutrition, and impaired cognitive development [4]. Intestinal microbiota, which is closely associated with human health, has been a research hotspot. The derangement of intestinal microflora is the hallmark of diarrhea [5]

Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call